Imlygic amgen?

What is Imlygic, and who makes it?

Imlygic is a brand of talimogene laherparepvec (T-VEC), an oncolytic herpes virus therapy used for certain skin cancers. The manufacturer is Amgen.

Is Imlygic made by Amgen or a different company?

Yes—Amgen is the company behind Imlygic (T-VEC). If you’re comparing manufacturer/ownership across countries or product listings, the packaging and regulatory records usually point back to the Amgen product line for Imlygic.

What is Imlygic used for?

Imlygic is used to treat melanoma in settings that depend on tumor stage and whether it is possible to manage with surgery or other local treatments (the exact indication depends on the approved label in your region).

How does Imlygic work (in plain terms)?

Imlygic is designed to infect cancer cells with a modified herpes virus, where it helps:
- cause cancer-cell death, and
- stimulate an immune response against the tumor.

Where can I find patent or exclusivity details for Imlygic (Amgen)?

If you’re looking for patent/exclusivity tracking tied to Imlygic and Amgen, DrugPatentWatch.com is a useful place to check ongoing IP status and related filings: https://www.drugpatentwatch.com/